Clinical Trial Update: A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update on using zoledronic acid to prevent cancer therapy-induced bone loss in premenopausal women with hormone receptor-negative breast …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Osteoporosis

Drugs mentioned

• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women | Phase 4 | Status: TERMINATED | Results posted: 2014-11-25